Market Overview

Peptide Synthesis: Worldwide Markets 2018-2023 - CAGR to Grow at 6.5% - Increasing Use of Peptides in Pharmaceutical Drugs is Driving Growth


Peptide Synthesis: Worldwide Markets 2018-2023 - CAGR to Grow at 6.5% - Increasing Use of Peptides in Pharmaceutical Drugs is Driving Growth

PR Newswire

DUBLIN, July 20, 2018 /PRNewswire/ --

The "Peptide Synthesis Market by Product (Reagent, Synthesizer, Chromatography), Technology (Solid Phase, Liquid Phase, and Hybrid & Recombinant), End User (Pharmaceuticals & Biotechnology, CRO), and Region - Global Forecast to 2023" report has been added to's offering.

Research and Markets Logo

The peptide synthesis market is projected to reach USD 426.4 million by 2023 from USD 310.5 million in 2018, at a CAGR of 6.5% during the forecast period.

Factors such as the growing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced peptide synthesizers are expected to drive the growth of the market. However, the lack of a unified set of regulations for therapeutic peptides is expected to restrain the growth of this market during the forecast period.

In this report, the peptide synthesis market has been segmented by product, technology, and end user. This report also provides market information based on key regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Based on product, peptide synthesis market has been segmented into reagents and equipment. The equipment segment has been subsegmented into peptide synthesizers, chromatography equipment, and lyophilizers. This segment is expected to grow at the highest CAGR in the next five years. Technological innovations, automation, and advancements in instruments; replacement of older equipment with new ones; increasing demand from the Asian market; and growing demand for synthesized peptides, are factors driving the high growth of this market.

By technology, the peptide synthesis market has been segmented into solid-phase synthesis, liquid-phase synthesis, and hybrid & recombinant technology. Solid-phase synthesis held the largest share of the peptide synthesis market in 2017 due to advantages such as ease of operation, easy purification, short production cycles, high-level automation, and synthesis capabilities of long peptides in small quantities of amino acids.

By end user, the global peptide synthesis market is segmented into pharmaceutical and biotechnology companies, contract development and manufacturing organizations, and academic and research institutes. The contract development and manufacturing organizations segment is projected to grow at the highest CAGR in the peptide synthesis market. Increasing demand for cost-effective peptide synthesis services in drug development activities and life science research is a key driver for this end-user segment.

North America dominated the peptide synthesis market, followed by Europe during the forecast period. In North America, the US is expected to hold the largest share of the peptide synthesis market due to increasing research activity and the growing prevalence of cancer and chronic diseases.

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period and countries such as Japan, China, and India are expected to provide significant growth opportunities for market players.

The prominent players in the peptide synthesis market are GenScript Biotech Corporation (China), AAPPTec (US), Bachem (Switzerland), AnaSpec (US), Biotage (Sweden), CEM Corporation (US), Gyros Protein Technologies (Sweden), Advanced ChemTech (US), Merck KGAA (Germany) and New England Peptide (US). Product launches and agreements, partnerships and collaborations were the major strategies adopted by these payers to maintain their positions in the peptide synthesis market.

Key Topics Covered

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology
2.1 Research Data
2.1.1 Secondary Sources Key Data From Secondary Sources
2.1.2 Primary Sources Key Data From Primary Sources
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Market Share Estimation
2.5 Assumptions for the Study

3 Executive Summary

4 Premium Insights
4.1 Peptide Synthesis: Market Overview
4.2 Europe: Peptide Synthesis Market, By Technology & End User (2017)
4.3 Peptide Synthesis Market: Geographic Snapshot
4.4 Peptide Synthesis: Geographic Mix

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers Increasing Use of Peptides in Pharmaceutical Drugs Increase in Research Activities and Availability of Funding for R&D Development of Advanced Peptide Synthesizers
5.2.2 Restraint Lack of A Unified Set of Regulations for Therapeutic Peptides
5.2.3 Opportunity Emerging Markets in the Asia Pacific Region
5.2.4 Challenge Issues Associated With the Route of Administration of Peptide Drugs

6 Peptide Synthesis Market, By Product
6.1 Introduction
6.2 Reagents
6.3 Equipment
6.3.1 Peptide Synthesizers
6.3.2 Chromatography Equipment
6.3.3 Lyophilizers

7 Peptide Synthesis Market, By Technology
7.1 Introduction
7.2 Solid-Phase Peptide Synthesis (SPPS)
7.3 Solution-Phase Synthesis (SPS)
7.4 Hybrid and Recombinant Technology

8 Peptide Synthesis Market, By End User
8.1 Introduction
8.2 Pharmaceutical and Biotechnology Companies
8.3 Contract Development and Manufacturing Organization/ Contract Research Organization
8.4 Academic and Research Institutes

9 Peptide Synthesis Market, By Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Rest of Asia Pacific
9.5 Latin America
9.6 Middle East and Africa

10 Competitive Landscape
10.1 Overview
10.2 Competitive Scenario
10.3 Growth Strategy Matrix
10.3.1 Acquisitions
10.3.2 Product Launches
10.3.3 Agreements, Partnerships, and Collaborations
10.3.4 Expansions

11 Company Profiles
11.1 Genscript Biotech
11.2 Merck KGaA
11.3 AAPPtec
11.4 Bachem Holdings
11.5 Anaspec (A Subsidiary of Kaneka Eurogentec S.A.)
11.6 Biotage
11.7 CEM Corporation
11.8 Gyros Protein Technologies
11.9 Advanced Chemtech
11.10 NEP (New England Peptide)

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:

SOURCE Research and Markets

View Comments and Join the Discussion!